Anne-Marie Cleton
- Name
- A.M. Cleton
- Jong Y. de, Oosterwijk J.G. van, Kruisselbrink A.B., Briaire I.H., Agrogiannis G., Baranski Madrigal Z., Cleven A.H., Cleton A.M., Water B. van de, Danen E.H.J. & Bovée J.V.M.G. (2016), Targeting survivin as a potential new treatment for chondrosarcoma of bone, Oncogenesis 5: e222.
- Peterse E.F.P., Cleven A.H.G., Jong Y. de, Briaire-de Bruijn I., Fletcher J.A., Danen E.H.J., Cleton A.M. & Bov'ee J.V.M.G. (2016), No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone, BMC Cancer 16: 475.
- Oosterwijk J.G. van, Herpers B.H.A., Meijer D., Briaire-Bruijn I.H. de, Cleton-Jansen A.M., Gelderblom H., Water B. van de & Bovée J.V.G.M. (2012), Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance, Annals of Oncology 23(6): 1617-1626.
- Lombaerts M., Wezel T. van, Philippo K., Dierssen J.W., Zimmerman R.M., Oosting J., Eijk R. van, Eilers P.H., Water B. van de, Cornelisse C.J. & Cleton A.M. (2006), E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines, British Journal of Cancer 94(5): 661-671.